Literature DB >> 9076581

An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats.

R Armamento-Villareal1, K Ziambaras, S H Abbasi-Jarhomi, A Dimarogonas, L Halstead, A Fausto, L V Avioli, R Civitelli.   

Abstract

Intermittent administration of parathyroid hormone (PTH) peptides increases bone density in animal and human models of osteoporosis. In vitro studies have demonstrated that PTH analogs lacking the first two amino acids can stimulate cell proliferation in certain cell systems, whereas fragments with an intact N terminus can be antimitogenic. We have tested whether the truncated PTH(3-38) fragment may be a better "anabolic analog" than PTH(1-38) by monitoring bone density and biomechanical properties of the femur in 6-month-old ovariectomized (OVX) rats. Either PTH fragment was administered subcutaneously (8 micrograms/100 g of body weight) 5 days/week, for 4 weeks, starting 1 week after surgery. During the entire study, untreated OVX rats lost 12.1 +/- 4.4% of their initial bone density. PTH(1-38) reversed the initial bone loss, leading to complete restoration of presurgery values after 4 weeks of treatment. Conversely, administration of PTH(3-38) resulted in 13.2 +/- 5.8% bone loss, while continuous estrogen infusion (10 micrograms/kg/day) prevented bone loss but did not reverse it. Sham-operated animals also experienced significant bone loss in the vehicle and PTH(3-38)-treated groups (-4.5 +/- 6.7%, and -7.6 +/- 2.8%, respectively), whereas a significant gain in bone density (+4.4 +/- 5.6%) was observed in the rats treated with PTH(1-38). A bone quality factor (index of strain energy loss) and the impact strength (resistance to fracture) were 25% and 44% lower in femurs explanted from OVX animals treated with either vehicle or PTH(3-38), compared with sham-operated animals. On the contrary, no difference was observed between OVX and control animals after treatment with PTH(1-38), indicating a preservation of the capacity to withstand mechanical stress. Thus, PTH(1-38) counteracts estrogen-dependent loss of mineral density and bone biomechanical properties and increases bone density in estrogen-replete animals. An intact N terminus sequence is necessary for this anabolic action of PTH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9076581     DOI: 10.1359/jbmr.1997.12.3.384

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  11 in total

1.  Parathyroid hormone signaling through low-density lipoprotein-related protein 6.

Authors:  Mei Wan; Chaozhe Yang; Jun Li; Xiangwei Wu; Hongling Yuan; Hairong Ma; Xi He; Shuyi Nie; Chenbei Chang; Xu Cao
Journal:  Genes Dev       Date:  2008-11-01       Impact factor: 11.361

2.  CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.

Authors:  Fei Liu; Sun-Kyeong Lee; Douglas J Adams; Gloria A Gronowicz; Barbara E Kream
Journal:  Bone       Date:  2007-02-01       Impact factor: 4.398

3.  Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts.

Authors:  Estelle N Bianchi; Serge L Ferrari
Journal:  Bone       Date:  2009-06-25       Impact factor: 4.398

4.  Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.

Authors:  Changjun Li; Weishan Wang; Liang Xie; Xianghang Luo; Xu Cao; Mei Wan
Journal:  Ann N Y Acad Sci       Date:  2015-04-02       Impact factor: 5.691

5.  beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice.

Authors:  Mary L Bouxsein; Dominique D Pierroz; Vaida Glatt; Deborah S Goddard; Fanny Cavat; Renée Rizzoli; Serge L Ferrari
Journal:  J Bone Miner Res       Date:  2004-12-06       Impact factor: 6.741

6.  Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts.

Authors:  Robert F Spurney; Patrick J Flannery; Sanford C Garner; Krairerk Athirakul; Shiguang Liu; Farshid Guilak; L Darryl Quarles
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

7.  The PTH-Gαs-protein kinase A cascade controls αNAC localization to regulate bone mass.

Authors:  Martin Pellicelli; Julie A Miller; Alice Arabian; Claude Gauthier; Omar Akhouayri; Joy Y Wu; Henry M Kronenberg; René St-Arnaud
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

8.  Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass.

Authors:  Edward C Hsiao; Benjamin M Boudignon; Wei C Chang; Margaret Bencsik; Jeffrey Peng; Trieu D Nguyen; Carlota Manalac; Bernard P Halloran; Bruce R Conklin; Robert A Nissenson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-22       Impact factor: 11.205

Review 9.  Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.

Authors:  Robert L Jilka
Journal:  Bone       Date:  2007-04-06       Impact factor: 4.398

10.  Cyclic AMP signaling in bone marrow stromal cells has reciprocal effects on the ability of mesenchymal stem cells to differentiate into mature osteoblasts versus mature adipocytes.

Authors:  Richard Kao; Weidar Lu; Alyssa Louie; Robert Nissenson
Journal:  Endocrine       Date:  2012-06-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.